Workflow
RadNet(RDNT)
icon
Search documents
RadNet, Inc. to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024
GlobeNewswire News Room· 2024-06-03 10:00
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time. There will be simultaneous and archived webcasts available at https:// ...
RadNet, Inc. to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024
Newsfilter· 2024-06-03 10:00
There will be simultaneous and archived webcasts available at https://wsw.com/webcast/jeff302/rdnt/1856896 and www.radnet.com under the "About RadNet'' menu section and "News and Press Releases'' sub-menu of the website. LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and ...
RadNet(RDNT) - 2024 Q1 - Quarterly Results
2024-05-10 22:58
Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA and Adjusted Earnings and Revises Upwards 2024 Financial Guidance Ranges LOS ANGELES, California, May 8, 2024 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost- effective, fixed-site outpatient diagnostic imaging services through a network of 375 owned and operated outpatient imaging centers, today reported financial results for its first quarter ...
RadNet(RDNT) - 2024 Q1 - Quarterly Report
2024-05-10 20:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other jurisdiction of incorporation or organization) 1510 Cotner Avenue Los Angeles, California 90 ...
RadNet(RDNT) - 2024 Q1 - Earnings Call Transcript
2024-05-09 22:14
RadNet, Inc. (NASDAQ:RDNT) Q1 2024 Results Conference Call May 9, 2024 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Dr. Howard Berger - Chairman, President & Chief Executive Officer Conference Call Participants Brian Trance - Jefferies John Ransom - Raymond James Andrew Mok - Barclays Yuan Zhi - B. Riley Securities Jim Sidoti - Sidoti & Company Operator Good morning, everyone, and welcome to the RadNet, Inc. First Quarter 2021 Financial Results Conferenc ...
RadNet(RDNT) - 2023 Q4 - Annual Results
2024-03-05 19:08
Imaging Center Segment Performance - Adjusted EBITDA for the Imaging Center segment in 2023 was $245.1 million, a 17.2% increase compared to 2022[2] - Revenue for the Imaging Center segment in 2023 was $1,604 million, a 12.5% increase compared to 2022[2] - 2024 guidance for the Imaging Center segment projects Total Net Revenue between $1,650 - $1,700 million, representing a growth of 5.3% - 8.5%[6] - 2024 guidance for the Imaging Center segment projects Adjusted EBITDA between $250 - $260 million, representing a growth of 11.4% - 15.8%[6] - Imaging Center segment performance: Revenue grew 8.6% to $415.3 million, Adjusted EBITDA increased 11.0% to $68.3 million, and same-center procedural volume grew 5.5% in Q4 2023[45][49] Digital Health Segment Performance - 2024 guidance for the Digital Health segment projects Total Net Revenue between $60 - $70 million, representing a growth of 21.0% - 41.2%[8] - 2024 guidance for the Digital Health segment projects Adjusted EBITDA Before Non-Capitalized R&D for DeepHealth Cloud OS & Generative AI between $12 - $14 million, representing a growth of 51.4% - 76.6%[8] - The Digital Health segment has over 500 outside customers and combines informatics businesses with AI operations[9] - Formation of Digital Health reporting segment: Combining AI operations with software and informatics businesses, with 2023 pro forma results showing $49.6 million in Revenue and $7.9 million in Adjusted EBITDA[60][61] AI Segment Growth and Investments - Non-Capitalized R&D investment in DeepHealth Cloud OS and generative AI was $1.3 million in Q4 2023[1] - Pre-tax losses related to the AI reporting segment were $5.0 million in Q4 2023[1] - The company expects significant growth in 2024 from AI revenue, particularly from Enhanced Breast Cancer Detection (EBCD) implementation and lung and prostate AI licensing in Europe[10] - AI segment growth: AI revenue surged 278.4% to $5.1 million in Q4 2023 and is expected to increase over 65% in 2024, with AI Adjusted EBITDA projected to break even by end of 2024[45][48] - Digital health initiatives: Migration to cloud-based solutions, development of DeepHealth OS suite, and expansion of AI-enhanced screening programs for breast, lung, and prostate cancer[48] Financial Performance and Metrics - Net income for 2023 was $30.3 million, a decrease from $33.6 million in 2022 and $44.3 million in 2021[19] - Net cash provided by operating activities in 2023 was $220.9 million, up from $146.4 million in 2022[19] - Total service revenue for Q4 2023 was $420.4 million, compared to $383.9 million in Q4 2022[20] - Adjusted EBITDA for Q4 2023 was $65.8 million, an increase from $57.2 million in Q4 2022[21] - Adjusted EBITDA for the full year 2023 was $232.3 million, up from $192.5 million in 2022[21] - Non-cash employee stock-based compensation for 2023 was $26.8 million, compared to $23.8 million in 2022[21] - Depreciation and amortization expenses for 2023 were $128.4 million, up from $115.9 million in 2022[19] - Net cash used in investing activities for 2023 was $201.5 million, a decrease from $246.9 million in 2022[19] - Proceeds from issuance of stock in 2023 were $245.8 million, compared to $0 in 2022[19] - EBITDA losses from the AI segment for 2023 were $12.8 million, down from $16.6 million in 2022[21] - Total current assets decreased from $579.276 million in 2022 to $367.184 million in 2023[22] - Total property, plant, equipment, and right-of-use assets slightly decreased from $1.200433 billion in 2022 to $1.169485 billion in 2023[22] - Total liabilities increased from $1.877114 billion in 2022 to $1.942455 billion in 2023[22] - Adjusted net income attributable to RadNet, Inc. common stockholders increased from $6.383 million in 2022 to $13.742 million in 2023[27] - Adjusted diluted net income per share attributable to RadNet, Inc. common stockholders increased from $0.11 in 2022 to $0.20 in 2023[27] - Total service revenue increased to $1,616,630 in 2023, up 13% from $1,430,061 in 2022[65] - Net income attributable to RadNet, Inc. common stockholders decreased to $3,044 in 2023 from $10,650 in 2022[65] - Cash and cash equivalents at the end of the period rose significantly to $342,570 in 2023 from $127,834 in 2022[66] - Basic net income per share attributable to RadNet, Inc. common stockholders dropped to $0.05 in 2023 from $0.19 in 2022[65] - Weighted average shares outstanding (basic) increased to 63,580,059 in 2023 from 56,293,336 in 2022[65] - Cash paid for interest during the period rose to $64,695 in 2023 from $39,151 in 2022[66] - Cost of operations, excluding depreciation and amortization, increased to $1,395,239 in 2023 from $1,264,346 in 2022[65] - Depreciation and amortization expenses grew to $128,391 in 2023 from $115,877 in 2022[65] - Interest expense increased to $64,483 in 2023 from $50,841 in 2022[65] - Cash paid for income taxes during the period rose to $1,587 in 2023 from $587 in 2022[66] Volume Growth and Procedural Metrics - MRI procedures increased from 352,009 in Q4 2022 to 398,625 in Q4 2023[35] - Total procedures increased from 2.376995 million in Q4 2022 to 2.565720 million in Q4 2023[35] - Volume growth across modalities: MRI volume increased 13.2%, CT volume grew 11.3%, and PET/CT volume rose 18.5% in Q4 2023 compared to Q4 2022[53] Expansion and Strategic Initiatives - 2024 expansion plans: Approximately a dozen new facilities to be opened, including entry into the Houston market through acquisition of seven imaging centers[47] - 2023 capital expenditures: $153.0 million, including $18.6 million for New Jersey Imaging Network and $19.8 million for equipment previously leased[62][63] Payor Class Breakdown - Commercial insurance accounted for 58.0% of payor class breakdown in Q4 2023[31] Record Financial Performance - RadNet reported record revenue and Adjusted EBITDA for Q4 2023 and released 2024 financial guidance[43] - Record Revenue and Adjusted EBITDA in Q4 2023: Revenue increased 9.5% to $420.4 million, with Adjusted EBITDA growing 15.0% to $65.8 million compared to Q4 2022[45][50] - Full-year 2023 results: Total Revenue increased 13.0% to $1,617 million, with Adjusted EBITDA growing 20.7% to $232.3 million compared to 2022[58] Financial Leverage and Liquidity - 2023 financial leverage improvement: Net debt to Adjusted EBITDA fell below 2.0x, with $342 million cash balance and Days Sales Outstanding of 32.0 at year-end 2023[46]
RadNet(RDNT) - 2023 Q4 - Earnings Call Transcript
2024-03-01 21:00
RadNet, Inc. (NASDAQ:RDNT) Q4 2023 Earnings Conference Call February 29, 2024, 10:300 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Howard Berger - Chairman, President & Chief Executive Officer Conference Call Participants Brian Tanquilut - Jefferies David MacDonald - SunTrust Gary Taylor - TD Cowen John Ransom - Raymond James Lawrence Solow - CJS Securities Edward Kressler - Angelo Gordon James Sidoti - Sidoti & Company Operator Good day, and welcome to the Ra ...
RadNet(RDNT) - 2023 Q4 - Annual Report
2024-02-29 21:57
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 1 ...
RadNet(RDNT) - 2023 Q3 - Earnings Call Transcript
2023-11-10 01:24
RadNet, Inc. (NASDAQ:RDNT) Q3 2023 Earnings Conference Call November 9, 2023 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Howard Berger - Chairman, President & Chief Executive Officer Conference Call Participants Jack Slevin - Jefferies Nathan Malewicki - Raymond James Larry Solow - CJS Securities Jim Sidoti - Sidoti & Company Rishi Parekh - JPMorgan Ed Kressler - TPG Angelo Gordon Operator Good day and welcome to the RadNet Third Quarter 2023 Financial ...
RadNet(RDNT) - 2023 Q3 - Quarterly Report
2023-11-09 22:22
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or Delaware 13-3326724 (State or oth ...